Related Experiment Video

Updated: Mar 30, 2026

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes
10:11

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes

Published on: September 27, 2014

37.2K

Getting the most from the Ebola vaccine success

Daniele Focosi1, Fabrizio Maggi2, Mauro Pistello3

  • 1North-Western Tuscany Blood Bank, Pisa University Hospital, Italy.

Vaccine
|November 12, 2015
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Optimized Interferon-gamma ELISpot Assay to Measure T Cell Responses in the Guinea Pig Model after Vaccination
08:13

Optimized Interferon-gamma ELISpot Assay to Measure T Cell Responses in the Guinea Pig Model after Vaccination

Published on: January 20, 2019

22.7K
Remote Laboratory Management: Respiratory Virus Diagnostics
14:56

Remote Laboratory Management: Respiratory Virus Diagnostics

Published on: April 6, 2019

33.8K

Related Experiment Videos

Last Updated: Mar 30, 2026

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes
10:11

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes

Published on: September 27, 2014

37.2K
Optimized Interferon-gamma ELISpot Assay to Measure T Cell Responses in the Guinea Pig Model after Vaccination
08:13

Optimized Interferon-gamma ELISpot Assay to Measure T Cell Responses in the Guinea Pig Model after Vaccination

Published on: January 20, 2019

22.7K
Remote Laboratory Management: Respiratory Virus Diagnostics
14:56

Remote Laboratory Management: Respiratory Virus Diagnostics

Published on: April 6, 2019

33.8K

Related Concept Videos

Cross-reactivity00:42

Cross-reactivity

33.8K
Overview
33.8K
Vaccinations01:51

Vaccinations

53.8K
Overview
53.8K
Vaccine Production01:23

Vaccine Production

57
Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
57
Vaccines01:21

Vaccines

42
Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the...
42

Articles linked to this work by shared authors, journal, and citation graph.

Chikungunya Virus: What a Transfusion Service Needs to Know.

Viruses·2026

New and novel pharmacotherapies for hemophilia A: an update.

Expert opinion on pharmacotherapy·2026

Convalescent Plasma Restores Viral Clearance After Anti-Spike Monoclonal Antibody Failure in Immunocompromised COVID-19 Patients: A Systematic Review and Meta-Analysis of Individual Patient Data.

Reviews in medical virology·2026

ConvMut: Exploration of Viral Convergent Mutations Along Phylogenies.

Viruses·2026

Challenges and Opportunities for Signal Detection During Public Health Emergencies: An Historical Re-evaluation of the Disproportionality Analysis of the ADR Reporting of Anti-COVID-19 Monoclonal Antibodies in Vigibase.

Drug safety·2026

Human Evolution: Between Hemorrhage and Thrombosis.

Seminars in thrombosis and hemostasis·2026

Comparing the potential impacts of seasonal immunisation against year-round immunisation to prevent RSV infant hospitalisations in Japan: A modelling study.

Vaccine·2026

Psychometric validity evidence for a measure of trust in U.S. public health actors for vaccine information.

Vaccine·2026

Measles outbreak risk in Afghanistan: provincial immunity gaps and epidemic potential following immunisation system disruption.

Vaccine·2026

Synergistic effect of AddaS03 and poly I:C adjuvants on antibody titers and Th1-biased T cell responses following RBD vaccination in BALB/c mice.

Vaccine·2026

Systematic review of the mutations in the active antigenic site Ø of the prefusion F protein of the Respiratory Syncytial Virus (RSV) following the implementation of monoclonal antibody prophylaxis.

Vaccine·2026

Elevating immunization as a political and economic priority in Africa: Reflections from the continental consensus on Africa's continental immunization strategy in november 2025 in Kigali, Rwanda.

Vaccine·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us